osteoclast differentiation factor rankl controls development progestin-driven mammary cancer 
breast cancer one common cancers humans will average affect one eight women lifetime united states europe1 womens health initiative million women study shown hormone replacement therapy associated increased risk incident fatal breast cancer23 particular synthetic progesterone derivatives progestins medroxyprogesterone acetate mpa used millions women hormone replacement therapy contraceptives markedly increase risk developing breast cancer show vivo administration mpa triggers massive induction key osteoclast differentiation factor rankl receptor activator nf-kappa b ligand mammary-gland epithelial cells genetic inactivation rankl receptor rank mammary-gland epithelial cells prevents mpa-induced epithelial proliferation impairs expansion cd49fhi stem-cell-enriched population sensitizes cells dna-damage-induced cell death deletion rank mammary epithelium results markedly decreased incidence delayed onset mpa-driven mammary cancer data show rankl/rank system controls incidence onset progestin-driven breast cancer 
